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Initial assessment 
on presentation 
• Take a detailed history from the patient and/or relatives 
• Perform a full physical examination, including baseline body weight and 
record the vital signs, including oxygen saturation 
• Order a set of investigations: FBC, U&E, LFT, glucose, magnesium, 
phosphate, bicarbonate, mycoplasma  serology, CXR, skin biopsy and 
baseline body weight 
• Initiate a primary management plan: 
1. establish peripheral venous access 
2. if patient cannot maintain adequate nutrition orally, insert a 
nasogastric tube and institute nasogastric feeding 
3. insert a urinary catheter if urogenital involvement is causing 
significant dysuria/retention 
(Strength of recommendation D (GPP)) 
Determination of 
drug causality 
• Identify causative agent and withdraw immediately 
(Strength of recommendation D) 
Prognostic 
scoring 
• Calculate SCORTEN within the first 24 hours 
(Strength of recommendation C) 
Care setting • A multi-disciplinary team should be convened, co-ordinated by a specialist 
in skin failure, usually  dermatology and/or plastic surgery, and including 
clinicians from intensive care, ophthalmology and skin-care nursing  
• Patients with greater than 10% BSA epidermal loss should be admitted 
without delay to a Burn Centre or ICU with experience of treating patients 
with SJS/TEN and facilities to manage the logistics of extensive skin loss 
wound care 
• Patients must be barrier-nursed in a side room controlled for humidity, on a 
pressure-relieving mattress with the ambient temperature raised to between 
25° and 28°C  
(Strength of recommendation D (GPP)) 
Skin management 
regimen 1  
 
Applicable to all 
patients in all 
settings 
• Employ strict barrier nursing to reduce nosocomial infections 
• Take swabs for bacterial and candidal culture from three areas of lesional 
skin, particularly sloughy or crusted areas, on alternate days throughout the 
acute phase 
• Administer systemic antibiotics only if there are clinical signs of infection 
 (Strength of recommendation D (GPP)) 
Skin management 
regimen 2 
 
This  may involve 
a conservative 
and/or surgical 
approach based 
on the specialist 
multi-disciplinary 
team’s daily 
review of the 
individual needs 
of the patient 
Institute a conservative approach in all patients as follows: 
• Regularly cleanse wounds and intact skin by irrigating gently using warmed 
sterile water, saline or an antimicrobial such as chlorhexidine (1/5000) 
• Apply a greasy emollient, such as 50% white soft paraffin with 50% liquid 
paraffin (50/50 WSP/LP), over the whole epidermis, including denuded 
areas 
• Apply a topical antimicrobial agent to sloughy areas only (choice should be 
guided by local microbiological advice). Consider Ag-containing 
products/dressings. 
• The detached, lesional epidermis may be left in situ to act as a biological 
dressing. Blisters should be decompressed by piercing and expression or 
aspiration of tissue fluid. 
• Apply non-adherent dressings to denuded dermis (suitable dressings 
include Mepitel™ or Telfa™).  
• A secondary foam or burn dressing should be used to collect exudate 
(suitable dressings include Exu-Dry®). 
 
Consider transfer to a Burn Centre in patients with TEN (>30% BSA 
epidermal loss) and evidence of the following: clinical deterioration, 
extension of epidermal detachment, sub-epidermal pus, local sepsis, 
wound conversion and/or delayed healing. In a Burn Centre conservative 
measures may be supplemented with a surgical approach. 
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• Remove necrotic/loose infected epidermis and clean wounds using a topical 
antimicrobial agent (e.g. betadine or chlorhexidine) under general 
anaesthetic 
• Consider debridment with VersajetTM  
• Physiological closure with Biobrane/ allograft /xenograft skin in patients with 
early presentation involving non infected and large confluent areas  
(Strength of recommendation D (GPP)) 
Fluid replacement 
regimen  
• Site venous lines through non-lesional skin, whenever possible, and 
change peripheral venous cannulas every 48 hours 
• Monitor fluid balance carefully: catheterize if appropriate/necessary 
• Establish adequate intravenous fluid replacement initially. Fluid 
replacement can be guided by urine output and other endpoint 
measurements. Individualized fluid management should be adjusted on a 
daily basis. 
• With improvement of SJS/TEN mouth involvement, oral administration of 
fluids should be progressively increased 
(Strength of recommendation D) 
Nutrition regimen • Provide continuous enteral nutrition throughout the acute phase 
• Deliver up to 20 to 25 kcal/kg/day during the early, catabolic phase and 25 
to 30 kcal/kg/day during the anabolic, recovery phase 
(Strength of recommendation C) 
Analgesia • Use a patient appropriate validated pain tool to assess pain in all conscious 
patients at least once a day 
• Patients should receive adequate analgesia to ensure comfort at rest, with 
the addition of supplementary opiates, as required 
• Additional analgesia may be needed to address increased pain associated 
with patient handling, re-positioning and dressing changes 
(Strength of recommendation D (GPP)) 
Supportive 
Therapeutic 
Measures 
• Immobile patients should receive low molecular weight heparin 
• Patients in whom enteral nutrition cannot be established should receive a 
proton pump inhibitor to reduce the risk of stress-related gastro-intestinal 
ulceration 
• Neutropenic patients may benefit from recombinant human G-CSF 
(Strength of recommendation C) 
Treatment of eye 
involvement 
• Daily ophthalmological review is necessary during the acute illness 
• Apply an ocular lubricant  (e.g. non-preserved hyaluronate or carmellose  
eye drops) every two hours through the acute illness 
• Ocular hygiene must be carried out each day by an ophthalmologist or 
ophthalmic-trained nurse 
• Application of topical corticosteroid drops (e.g. non-preserved 
dexamethasone 0.1% twice a day) may reduce ocular surface damage 
• Administer a broad-spectrum topical antibiotic as prophylaxis (e.g. 
moxifloxacin drops four times a day) in the presence of corneal fluorescein 
staining or frank ulceration 
• In the unconscious patient, prevention of corneal exposure is essential 
(Strength of recommendation D (GPP)) 
Treatment of 
mouth 
involvement 
• Daily oral review is necessary during the acute illness 
• Apply white soft paraffin ointment to the lips every two hours through the 
acute illness  
• Clean the mouth daily with warm saline mouthwashes or an oral sponge 
• Use an anti-inflammatory oral rinse or spray containing benzydamine 
hydrochloride every three hours, particularly before eating 
• Use an anti-septic oral rinse containing chlorhexidine twice a day 
• Use a potent topical corticosteroid mouthwash (e.g. betamethasone 
sodium phosphate) four times a day 
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(Strength of recommendation D (GPP)) 
Treatment of 
urogenital 
involvement 
• Daily urogenital review is necessary during the acute illness 
• Apply white soft paraffin ointment to the urogenital skin and mucosae every 
four hours through the acute illness  
• Use a potent topical corticosteroid ointment once a day to the involved, but 
non-eroded, surfaces 
• Use a silicone dressing  (e.g. MepitelTM)  to eroded areas 
(Strength of recommendation D (GPP)) 
Treatment of 
airway 
involvement 
• Respiratory symptoms and hypoxaemia on admission should prompt early 
discussion with an intensivist and rapid transfer to an ICU or Burn Centre, 
where fibre-optic bronchoscopy should be undertaken 
 (Strength of recommendation D (GPP)) 
Active therapy •  If active therapy is instituted it should be given, ideally, under the 
supervision of a specialist skin failure MDT in the context of clinical 
research and/or case registry 
(Strength of recommendation D) 
Discharge and 
follow-up 
• Give the patient written information about drug(s) to avoid 
• Encourage the patient to wear a MedicAlert bracelet 
• Drug allergy should be documented in the patient’s notes; all doctors 
involved in the patient’s care should be informed 
• Report the episode to the national pharmacovigilance authorities 
• Organize an out-patient clinic appointment, and if required  an 
ophthalmology out-patient appointment, within a few weeks of discharge 
• Refer for review to unit with appropriate sub-speciality interest 
(Strength of recommendation D (GPP)) 
Diagnostic testing • Routine drug hypersensitivity testing is not recommended following an 
episode of SJS/TEN. 
• Seek specialist advice on hypersensitivity testing where: 
1. the culprit drug is not known or 
2. medication avoidance is detrimental to the individual or  
3. accidental exposure is possible 
(Strength of recommendation D (GPP)) 
 
 
SUPPORTING INFORMATION 
Additional supporting information including the search strategy may be found in the full 
online version of this article here: http://dx.doi.org/10.1016/j.bjps.2016.01.034. 
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